Novel agents in acute myeloid leukemia

Ahmed Aribi, Farhad Ravandi, Frank Giles*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations

Abstract

In the past 40 years, advances in supportive care and development of chemotherapeutic agents have led to improved outcomes in patients with acute myeloid leukemia. High relapse rates following remission have led to extensive efforts to develop techniques and regimens for detecting and eliminating minimal residual disease. However, the best postremission therapy has not been identified. Better understanding of the biology and the molecular pathogenesis of AML has led to the development of new, more specific agents and strategies for AML treatment. Targeted therapy has improved outcomes in some patients. Most of the new agents are less toxic then their predecessors, and they can be used in combination with the more intensive traditional regimens.

Original languageEnglish (US)
Pages (from-to)77-91
Number of pages15
JournalCancer Journal
Volume12
Issue number2
StatePublished - Mar 2006

Keywords

  • Acute myeloid leukemia
  • New agents
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Novel agents in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this